Study findings first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA. Successful CS tapering was achieved within 20 weeks in almost half of patients (44...

Read more...